Antidepressants are the most commonly consumed class of
therapeutics in the United States, prescribed to more than 270 million patients
each year. Ketamine, an NMDA receptor antagonist used as an anesthetic in human
and veterinary medicine, can also be effective in treating depression. The
drug’s side effects, such as hallucinations or psychotic symptoms, however,
have made it a widely used and dangerous recreational drug referred to as
“Special K.”
The hallucinogenic and psychotic side effects hinder the
interpretation of its clinical activity and limit its use as a therapeutic
option for many patients. As the dangers of mental illness becomes more and
more evident in our society, researchers are racing to find an adequate
antidepressant alternative without the psychotic adverse effects.
According to a recent article in the Nature Reviews research
journal, scientists have done just that. Monica Hoyos Flight’s article, “Phase
2 boost for glutamate-targeted antidepressants,” discusses the results of a
phase 2 trial that suggest lanicemine as an alternative antidepressant with
minimal adverse psychotomimetic effects. Flight also names several NMDA
receptor blocking agents, including VistaGen Therapeutic’s AV-101.
Scientists at Yale University in collaboration with
AstraZeneca conducted a trial to study 152 patients with moderate-to-severe
depression and a weak response to antidepressants. Like ketamine, lancemine
showed efficacy as an NMDA receptor antagonist, a key feature in bringing
relief of depressive symptoms. Results showed a significant improvement in the
level of depression in patients administered lanicemine vs. placebo, without
hallucinations or psychotic symptoms.
But for lanicemine to gain approval and clinical acceptance,
it must demonstrate robust effects comparable to ketamine, provide rapid onset
relief, and have a toxicology profile that shows safety if the drug is taken
daily.
“The race is on to introduce safe and effective rapidly
acting antidepressants for the most seriously ill mood disorder patients,”
Flight quotes Sanjay J. Mathew, at the Michael E. Debakey VA Medical Center in
Houston, Texas, as saying. “There are multiple such agents in early phases of
development, including S-ketamine (the S-isomer of the racemic ketamine),
GLYX-13 (a partial NMDA receptor agonist) and AV-101, a selective blocker of
the regulatory GlyB site of the NMDA receptor.”
AV-101 is VistaGen’s lead small molecule drug candidate,
which has successfully completed phase 1 development in the U.S. for the
treatment of neuropathic pain. The company has been awarded more than $8.8
million from the Nation Institute of Health for further development of AV-101,
and VistaGen believes that its phase 1 safety program will enable phase 2
development of the drug candidate for neuropathic pain, other neurological
conditions and depression.
With researchers and scientists from some of the nation’s
leading academic institutions conducting studies for the highly sought
discovery of an alternative to ketamine for the treatment of depression,
VistaGen has positioned itself for potential among the ranks of leading
candidates.
For more information, visit www.vistagen.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment